Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Gut

• Publication date

  2004-08-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1136/gut.2003.031336PMID 15306598PMCID PMC1774214
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response

  2003influential reference
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Analysis of Sequence Configurations of the ISDR, PKR-Binding Domain, and V3 Region as Predictors of Response to Induction Interferon-α and Ribavirin Therapy in Chronic Hepatitis C Infection

  2002cited by this paper
• Management strategies using pharmacogenomics in patients with severe HCV‐1b infection: A decision analysis

  2002cited by this paper
• Hepatitis C Virus Nonstructural 5A Protein and Interferon Resistance: a New Model for Testing the Reliability of Mutational Analyses

  2002cited by this paper
• Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response

  2001cited by this paper
• Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection.

  2001cited by this paper
• Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C

  2001cited by this paper
• NS5A mutations predict biochemical but not virological response to interferon‐α treatment of sporadic hepatitis C virus infection in European patients

  2001cited by this paper
• Variations within hepatitis C virus E2 protein and response to interferon treatment.

  2001cited by this paper
• The NS5a gene of hepatitis C virus in patients treated with interferon‐α

  2000cited by this paper
• Integrity of the NS5A (amino acid 2209 to 2248) region in hepatitis C virus 1b patients non-responsive to interferon therapy.

  2000cited by this paper
• Prospective Characterization of Full-Length Hepatitis C Virus NS5A Quasispecies during Induction and Combination Antiviral Therapy

  2000cited by this paper
• Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon.

  2000cited by this paper
• Mutations in the E2‐PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment

  2000cited by this paper
• Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?

  1999cited by this paper
• Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon‐sensitive virus replication

  1999cited by this paper
• Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy.

  1999cited by this paper
• The non‐structural 5A protein of hepatitis C virus

  1999cited by this paper
• Mutations in the NS5A region do not predict interferon‐responsiveness in American patients infected with genotype 1b hepatitis C virus

  1999cited by this paper
• Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response.

  1999cited by this paper
• Mutations in the NS5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis.

  1999cited by this paper
• Efficacy and changes of the nonstructural 5A GENE by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV-RNA.

  1999cited by this paper
• The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus.

  1998cited by this paper
• The "interferon sensitivity determining region" of hepatitis C virus is a stable sequence element.

  1998cited by this paper
• Predictive factors in eradicating hepatitis C virus using a relatively small dose of interferon

  1998cited by this paper
• Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation

  1998cited by this paper
• Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome.

  1998cited by this paper
• Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity.

  1998cited by this paper
• Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common european hepatitis C virus genotypes

  1998cited by this paper
• The interferon sensitivity determining region: All hepatitis C virus isolates are not the same

  1997cited by this paper
• Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients.

  1997cited by this paper
• Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon‐β therapy

  1997cited by this paper
• Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa

  1997cited by this paper
• Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.

  1997cited by this paper
• Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitis C virus 1b infection

  1997cited by this paper
• Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity–determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

  1997cited by this paper
• Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b

  1997cited by this paper
• Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

  1996cited by this paper
• Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

  1996cited by this paper
• Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

  1996cited by this paper
• Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region.

  1995cited by this paper
• Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C

  1995cited by this paper
• CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

  1994cited by this paper
• A simple method for displaying the hydropathic character of a protein.

  1982cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe disease

  2025cites this paper
• The Relationship Between HCV-NS5A Gene Mutations and Resistance to Combination Therapy in Patients with HCV- Genotype 1-B.

  2021cites this paper
• Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions

  2021cites this paper
• Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C

  2020cites this paper
• Determination of Sustained Virological Response in Hepatitis C Virus Genotypes by the Number of Mutations in the E2 and NS5A-ISDR Regions: A Meta-Analysis

  2018cites this paper
• Genome-to-genome analysis highlights the impact of the human innate and adaptive immune systems on the hepatitis C virus

  2017cites this paper
• Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment

  2017cites this paper
• Genome-to-genome analysis highlights the impact of the human innate and adaptive immune systems on the hepatitis C virus

  2017cites this paper
• Development of tools to investigate resistance of HCV genotype 3 to NS5A inhibitors

  2017cites this paper
• Short interval change in hepatitis C hypervariable region 1 in chronic infection.Are there treatment windows in the envelope

  2016cites this paper
• Naturally Occurring HCV NS5A/B Inhibitor Resistance-Associated Mutations to Direct-Acting Antivirals

  2016cites this paper
• Developing new models to predict treatment outcome in patients with chronic hepatitis C infection

  2016cites this paper
• Genome-to-genome analysis reveals the impact of the human innate and 1 adaptive immune systems on the hepatitis C virus 2

  2016cites this paper
• Identification Of Mutation Sites In Hepatitis C Virus Genotype 3a In Non-Responders To Combination Therapy With Interferon- Αlfa And Ribavirin In Residents Of Khyber Pakhtunkhwa Province Pakistan.

  2016influential citation
• Viral Variation and Response to Therapy

  2016cites this paper
• The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients

  2016cites this paper
• A Novel Approach to Identify Candidate Prognostic Factors for Hepatitis C Treatment Response Integrating Clinical and Viral Genetic Data

  2015cites this paper
• Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy

  2015cites this paper
• Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1.

  2015cites this paper
• The role of HCV proteins on treatment outcomes

  2015cites this paper
• Interferon sensitivity-determining region of hepatitis C virus influences virus production and interferon signaling

  2015cites this paper
• Vitamin D‐related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C

  2015cites this paper
• Efecto del tratamiento antirretroviral en la respuesta virológica a interferón pegilado y ribavirina en pacientes coinfectados por el virus de la inmunodeficiencia humana y el virus de la hepatitis C

  2015cites this paper
• Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy

  2015cites this paper
• Prediction of hepatitis C virus interferon/ribavirin therapy outcome based on viral nucleotide attributes using machine learning algorithms

  2014cites this paper
• Viral Factors Associated with Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection

  2014cites this paper
• Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection

  2014cites this paper
• Chronic hepatitis C: predictors of treatment response in Estonian patients

  2014cites this paper
• Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

  2014cites this paper
• New evidence of replication of hepatitis C virus in short-term peripheral blood mononuclear cell cultures.

  2014cites this paper
• Quantitation of substitutions at amino acid 70 in hepatitis C virus genotype 1b

  2014cites this paper
• Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin‐28B

  2013cites this paper
• Sequencing of the Hepatitis C Virus: A Systematic Review

  2013cites this paper
• Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin

  2013cites this paper
• Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin

  2013cites this paper
• Chapter 99 – Viral Hepatitis

  2013cites this paper
• Relevance of Baseline Viral Genetic Heterogeneity and Host Factors for Treatment Outcome Prediction in Hepatitis C Virus 1b-Infected Patients

  2013cites this paper
• Analysis of HCV quasispecies dynamic under selective pressure of combined therapy

  2013cites this paper
• Amino Acid Polymorphisms Within the Entire HCV NS5A Region in Estonian Chronic HCV 1b Patients With Different Treatment Response

  2013cites this paper
• A Semi-Supervised Ensemble Learning Method for Finding Discriminative Motifs and its Application

  2013cites this paper
• Laboratory Methods for Diagnosis and Management of Hepatitis C Virus Infection

  2013cites this paper
• Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4+ T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load

  2012cites this paper
• Mutation Analysis of Protein Kinase Binding Domain of HCV NS5A Gene Isolated from Patients with Chronic Hepatitis C

  2012cites this paper
• Plasticity of the Hepatitis C Virus Genome

  2012cites this paper
• Epistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance.

  2012influential citation
• Natural killer cells in hepatitis C virus infection

  2012cites this paper
• A study of the natural history of hepatitis C infection within a geographically determined population (Trent HCV study)

  2012cites this paper
• Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.

  2012cites this paper
• Induction of IL-6 and CCL5 (RANTES) in human respiratory epithelial (A549) cells by clinical isolates of respiratory syncytial virus is strain specific

  2012cites this paper
• Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV.

  2012cites this paper
• Discovery of critical host factor, IL‐28B, associated with response to hepatitis C virus treatment

  2012cites this paper
• Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.

  2012cites this paper
• Mutational Analysis of Various Sub-Genomic Regions of HCV and Their Role in Interferon Therapy Response

  2012cites this paper
• Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b

  2012cites this paper
• Coinfección HIV-Hepatitis C: análisis molecular de factores genéticos del HCV que influyen sobre la respuesta al interferón

  2012cites this paper
• RNA-HCV viral load in serum, peripheral blood mononuclear cells and liver in children with chronic hepatitis C.

  2012cites this paper
• STRATEGIES FOR PREVENTION AND TREATMENT OF HEPATITIS C VIRUS INFECTION

  2012cites this paper
• Sequence Heterogeneity in NS5A of Hepatitis C Virus Genotypes 2a and 2b and Clinical Outcome of Pegylated-Interferon/Ribavirin Therapy

  2012cites this paper
• Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single‐nucleotide polymorphism of interleukin‐28B with the response to combination therapy with pegylated‐interferon‐alpha 2b and ribavirin

  2012cites this paper
• Acute HCV in HIV positive men; viral evolution and cellular immune responses

  2011cites this paper
• Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment

  2011cites this paper
• Genetic Heterogeneity of Hepatitis C Virus in Association with Antiviral Therapy Determined by Ultra-Deep Sequencing

  2011cites this paper
• Mechanisms of non-response to antiviral treatment in chronic hepatitis C.

  2011cites this paper
• Novel findings for the development of drug therapy for various liver diseases: Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C.

  2011cites this paper
• Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics

  2011cites this paper
• Prediction of response to peginterferon‐alfa‐2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b

  2011cites this paper
• The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals

  2011cites this paper
• Mutations in two PKR‐binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness

  2011influential citation
• IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.

  2011cites this paper
• Reappraisal of the importance of mutations in the NS5A‐PKR‐binding domain of hepatitis C‐1b virus in the era of optimally individualized therapy

  2011cites this paper
• Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg‐interferon and ribavirin therapy

  2011cites this paper
• Liver Interleukin-8 Messenger RNA Expression and Interferon Sensitivity-Determining Region Mutations Relate to Treatment Response in Hepatitis C 1B

  2011cites this paper
• Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy

  2011cites this paper
• Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis

  2011cites this paper
• Effects of Mutation Number in Interferon Sensitivity Determining Region on Peripheral Blood CD4-Positive T Cell Subsets (TH1, TH2) in Chronic Hepatitis C Patients With Hepatitis C Virus Genotype 1b a and High Viral Load

  2011cites this paper
• The NS5A Domain II of HCV: Conservation of Intrinsic Disorder in Several Genotypes

  2011cites this paper
• Hepatitis C Virus Genotypes

  2011cites this paper
• Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.

  2011cites this paper
• Mutaciones en las regiones E2-PePHD, NS5A-PKRBD, NS5A-ISDR y NS5A-V3 del virus de la Hepatitis C Genotipo 1 y su relación con la respuesta al tratamiento con interferón pegilado y ribavirina

  2011influential citation
• [Current options for predicting therapeutic response in chronically infected patients with hepatitis C virus genotype 1].

  2011cites this paper
• Coevolution of the Hepatitis C Virus Polyprotein Sites in Patients on Combined Pegylated Interferon and Ribavirin Therapy

  2011cites this paper
• Clinical evaluation of a colorimetric oligonucleotide chip for genotyping hepatitis C virus.

  2010cites this paper
• [Mutations within the interferon sensitivity determining region in Korean patients infected with hepatitis C virus genotype 1b].

  2010cites this paper
• Clinical relevance of genetic heterogeneity in HCV

  2010cites this paper
• Regulation of PKR by HCV IRES RNA: importance of domain II and NS5A.

  2010cites this paper
• Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors

  2010cites this paper
• Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

  2010cites this paper
• HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

  2010cites this paper
• Development of an intra- and intergenotypic HCV cell culture method to phenotype and assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1-6

  2010cites this paper
• Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis.

  2010cites this paper
• Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response

  2010cites this paper
• Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin.

  2010cites this paper
• Sequencing of E 2 and NS 5 A regions of HCV genotype 3 a in Brazilian patients with chronic hepatitis

  2010cites this paper
• Genomics and the Management of Hepatitis

  2010cites this paper
• Baseline Prediction of Combination Therapy Outcome in Hepatitis C Virus 1b Infected Patients by Discriminant Analysis Using Viral and Host Factors

  2010cites this paper
• λ‐Interferons and the single nucleotide polymorphisms: A milestone to tailor‐made therapy for chronic hepatitis C

  2010cites this paper
• Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

  2010cites this paper
• HCV Genetic Elements Determining the Early Response to Peginterferon and Ribavirin Therapy

  2010cites this paper
• Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin.

  2010cites this paper
• Evolution of Interferon-Based Therapy for Chronic Hepatitis C

  2010cites this paper